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1Introduction
Within the last 40 years, cancer survival rates have doubled 
in the UK [1], mainly due to advances in treatment, and 
the increased detection of cancer at an early stage [2]. 
In England and Wales, approximately 50% of adult cancer 
patients diagnosed in 2010 to 2011 are predicted to survive 
10 years or more [1]. In the US, the 5- year relative sur-
vival rate for all cancers diagnosed in 2004–2010 was 
68%, an increase from 49% in 1975–1977 [3]. Side- effects 
of cancer treatment and possible underlying etiological 
mechanisms, such as IGF- 1 metabolism, are thought to 
be implicated in the development of second primary 
cancers (SPCs). Therefore, identifying which cancer sur-
vivors have a high risk of developing SPCs is crucial.
It is well known that smoking [4, 5], obesity [6, 7], 
and insulin resistance [8, 9] are risk factors for the 
development of first primary cancers. However, the role 
of these risk factors in the development of SPCs in 
cancer survivors is less clear. There is some evidence 
that SPCs may be the result of genetic and hormonal 
risk factors [10–12], of late effects of chemo- and radio-
therapy [2, 13], smoking and alcohol effects [14, 15], 
as well as nonmodifiable variables such as age and gen-
der. For instance, a study based on the Swedish Family- 
Cancer Database concluded that, compared with the 
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Abstract
Cancer survival rates are increasing, and as a result, more cancer survivors are 
exposed to the risk of developing a second primary cancer (SPC). It has been 
hypothesized that one of the underlying mechanisms for this risk could be 
mediated by variations in insulin- like growth factor- 1 (IGF- 1). This review sum-
marizes the current epidemiological evidence to identify whether IGF- 1 plays a 
role in the development of SPCs. IGF- 1 is known to promote cancer develop-
ment by inhibiting apoptosis and stimulating cell proliferation. Epidemiological 
studies have reported a positive association between circulating IGF- 1 levels and 
various primary cancers, such as breast, colorectal, and prostate cancer. The 
role of IGF- 1 in increasing SPC risk has been explored less. Nonetheless, several 
experimental studies have observed a deregulation of the IGF- 1 pathway, which 
may explain the association between IGF- 1 and SPCs. Thus, measuring serum 
IGF- 1 may serve as a useful marker in assessing the risk of SPCs, and therefore, 
more translational experimental and epidemiological studies are needed to further 
disentangle the role of IGF- 1 in the development of specific SPCs.
Cancer Medicine
Open Access
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general population, males and females diagnosed with 
an initial primary cancer were 1.3–1.6 times more likely 
to develop a second cancer, respectively [16].
Epidemiological evidence suggests that survivors of cer-
tain types of cancers have a higher risk of developing 
SPCs. For example, contralateral breast cancer is the most 
common SPC that develops in patients diagnosed with a 
first breast cancer, accounting for approximately 50% of 
all SPCs [17]. Furthermore, breast cancer has emerged 
as the most common solid cancer among female survivors 
of Hodgkin’s lymphoma (diagnosed in childhood), which 
is largely due to the high- dose chest irradiation for 
Hodgkin’s lymphoma [2, 18]. In addition, urological can-
cers (bladder, kidney, testes, and penile cancers) are con-
sistently more prevalent among men with prostate cancer 
[19]. Indeed, it has been hypothesized that variations in 
the insulin- like growth factor (IGF) pathway, specifically 
IGF- 1 and its binding protein 3 (IGFBP- 3), could account 
for the increased risk of SPCs [20].
Recently, several studies have identified IGF- 1 to be 
associated with an increased risk of developing a number 
of common cancers, including lung [21], breast [22], 
colorectal [23], and prostate [24]. Circulating levels of 
IGF- 1 have been linked to the development of SPCs in 
men with head and neck squamous cell carcinoma [20]. 
However, so far a role of IGF- 1 in development of SPCs 
following diagnosis of prostate cancer, breast cancer, colo-
rectal cancer, or lung cancer has not been analyzed. In 
addition, a disorder known as Laron syndrome which is 
associated with low circulating levels of IGF- 1 and IGFBP- 3 
[25] are protected from developing cancer, but instead 
can develop diabetes and cardiovascular disease [26].
With the increase in number of cancer survivors, the 
long- term health outcomes of this population need to be 
carefully examined. Approximately, one in five cancers is 
diagnosed in those with a previous diagnosis of cancer, 
and hence, these “second primary cancers” are a leading 
cause of morbidity and mortality among cancer survivors 
[27]. It is therefore of interest to investigate the role of 
IGF- 1 in the development of various SPCs as it can help 
us understand the potential underlying mechanism for 
carcinogenesis. This review therefore aims to identify 
whether IGF- 1 plays a role in the development of SPCs, 
by assessing epidemiological evidence available to date.
Literature Review
We used a computerized literature search database 
(PubMed and EMBASE) to identify full text and abstract 
studies of English language, using human subjects and 
published between the years 1999 and 2015. Searches were 
performed with and without the Medical Subject Heading 
(MeSH) terms for “cancer”, “breast cancer”, “lung cancer”, 
“prostate cancer”, “colorectal cancer”, and “meta analysis”, 
combined with the keywords “second primary cancer” 
and “IGF 1”. All references of the selected articles were 
checked using hand searches.
IGF- 1 in First Primary Cancers
This section provides an overview of evidence for the 
emerging role of IGF- 1 in the development of first pri-
mary cancers, with a focus on epidemiological studies 
(Table 1) as well as experimental studies investigating the 
underlying biological mechanisms.
IGF- 1 is a single- chain polypeptide growth factor [28–30] 
that is related to insulin and IGF- 2 [31]. IGF- 1 stimulates 
cell growth, proliferation, and differentiation, and is essen-
tial for normal organismal growth and development [32, 
33]. IGF- 1 binds to the insulin- like growth factor 1 recep-
tor (IGF- 1R), which is a tyrosine kinase receptor [34]. 
IGF- 1 has a higher binding affinity than IGF- 2 for IGF- 1R. 
IGF- 1R initiates a cascade of downstream signal transduc-
tion pathways known to be involved in cell growth, pro-
liferation, and cancer, including Ras/Raf/ERK and PI3K/
Akt/mTOR [35]. The majority of IGF- 1 found in the 
circulation is produced by the liver, functioning as an 
endocrine hormone. IGF- 1 is also produced in other organs 
where autocrine or paracrine mechanisms have a role [36]. 
Ample evidence indicates that IGF- 1 and IGF- 1R are 
important for growth and survival of cancer cells [37, 
38] (Fig. 1). The expression of the IGF- 1 gene is primarily 
regulated by growth hormone (GH), and to a smaller 
extent by various other hormones [35]. By contrast, IGF- 1 
that is synthesized locally in an autocrine or paracrine 
manner may stimulate growth of some cancers [36]. The 
circulating levels of IGF- 1 change markedly with age, 
peaking at puberty, and slowly declining with increasing 
age; this fluctuation is regulated by GH, which itself has 
mitogenic and proliferative properties [35]. However, in 
other cell types, for example, cartilage cells, the growth- 
stimulating effects of IGF- 1 are GH- independent [39]. 
Furthermore, GH deficiency is the most common disorder 
seen in survivors of childhood cancer, and there are con-
cerns regarding its use in treating cancer survivors as it 
might increase the risk of SPCs [40]. Although IGF- 1 
possesses antiapoptotic, cell survival, and transforming 
activities, it is not classed as an oncogene.
Breast cancer
Findings to date on the role of IGF- 1 in breast cancer 
development vary depending on the study. An early case–
control study conducted in 1993 demonstrated that cir-
culating levels of IGF- 1 were higher in women with breast 
cancer compared to women without breast cancer [41]. 
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Table 1. Studies of cancer risk related to IGF- 1 level.
Author (Year) Control (n) Cases (n) Cancer risk related to IGF- 1 level Reference
Breast cancer
Peyrat (1993) 92 44 Median concentrations: 26 ng/mL (BCa) 
versus 20 ng/mL (controls)
[38]
Endogenous Hormones and Breast 
Cancer Collaborative Group 
(2010)
1839 1032 OR for BCa in the highest versus lowest 
fifth of IGF1 concentration was 1.28 
(95% CI: 1.14–1.44; P < 0.0001)
[39]
Rinaldi (2006) 312 202 Highest versus lowest quintile OR 1.38 
(95% CI: 1.02–1.86; P = 0.01) for 
women who develop breast cancer after 
50 years of age
[40]
Kaaks (2014) 259 193 OR=1.41 (95% CI: 1.01–1.98; P = 0.01 for 
the highest versus lowest quartile, for 
ER+ breast tumors overall (pre- and 
postmenopausal women combined)
[41]
Baglietto (2007) 42961 119 HR for BCa comparing the fourth with the 
first quartiles was 1.20 (95% CI: 
0.87–1.65).
[42]
19542 versus 736 68 versus 9 HR for BCa in older women comparing the 
fourth with the first quartiles (+60 years) 
was 1.61 (95% CI: 1.04–2.51) versus 
0.60 (95% CI: 0.25–1.45) for younger 
women (<50 years)
Renehan (2004) Meta- analysis of 4 
studies
Meta- analysis of 4 
studies
High concentrations of IGF- 1 were 
associated with an increased risk of 
premenopausal BCa (OR comparing 75th 
with 25th percentile 1.65, 95% CI: 
1.26–2.08; P < 0.001)
[44]
Shi (2004) 1306 779 Premenopausal women: Nearly 40% 
increase in BCa risk among those who 
had higher IGF- 1 in the circulation 
(overall OR 1.39, 95% CI: 1.16–1.66).
[45]
1552 911 No association in postmenopausal women 
(overall OR 0.93, 95% CI: 0.80–1.10).
Sugumar (2004) 1471 764 Subjects with higher circulating levels of 
IGF- 1 had increased risk of premenopau-
sal BCa with an OR of 1.74 (95% CI: 
0.97–3.13; P = 0.06)
[46]
Schernhammer (2006) 158 79 RR for top versus bottom quartile of IGF- 1 
was 0.98 (95% CI: 0.69–1.39; P = 0.77)
[47]
Hankinson (1998) 92 46 Postmenopausal women: No association 
between IGF- 1 concentrations and BCa 
risk (top vs. bottom quintile of IGF- 1, 
RR = 0.85 [95% CI: 0.53–1.39]).
[22]
35 35 RR of BCa among premenopausal women 
by IGF- 1 concentration (top vs. bottom 
tertile) was 2.33 (95% CI: 1.06–5.16; 
P = 0.08)
Lung cancer
Ahn (2006) 101 38 OR for LCa risk by IGF- 1 concentrations 
(highest vs. lowest quartile) was 0.69 
(95% CI: 0.41–1.15); P = 0.26
[51]
London (2002) 159 51 OR for LCa risk by IGF- 1 concentrations 
(highest vs. lowest quartile) was 0.73 
(95% CI: 0.43–1.24); P = 0.80
[53]
Lukanova (2001) 47 23 OR for LCa risk by IGF- 1 concentrations 
(highest vs. lowest quartile) was 0.79 
(95% CI: 0.29–2.19); P = 0.53
[54]
(Continued)
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Since then, several epidemiological studies have reported 
that higher circulating levels of IGF- 1 are associated with 
an increased risk of breast cancer [22, 42–45]. This may 
arise as higher levels of IGF- 1 are associated with accel-
eration of early carcinogenesis [36]. More recently, three 
meta- analyses demonstrated positive associations between 
IGF- 1 and risk of breast cancer among premenopausal, 
but not postmenopausal women [46–48]. A study by 
Schernhammer et al. aims to explain these observations 
by showing that premenopausal women with high IGF- 1 
Author (Year) Control (n) Cases (n) Cancer risk related to IGF- 1 level Reference
Morris (2006) 11,072 843 Meta- analysis: OR for LCa risk by IGF- 1 
concentrations (highest vs. lowest 
quartile) was 1.02 (95% CI: 0.80–1.31); 
P = 0.64
[55]
Yu (1999) 54 74 High plasma levels of IGF- 1 were 
associated with an increased risk of LCa 
(OR = 2.06; 95% CI: 1.19–3.56; 
P = 0.01)
[21]
Chen (2009) Meta- analysis of 6 
studies
Meta- analysis of 6 
studies
Pooled OR for LCa risk by IGF- 1 concentra-
tions (highest vs. lowest quartile) was 
0.87 (95% CI: 0.60–1.13)
[56]
Cao (2012) Meta- analysis of 6 
studies
Meta- analysis of 6 
studies
OR for LCa risk by IGF- 1 concentrations 
(highest vs. lowest quartile) was 1.05 
(95% CI: 0.80–1.37); P = 0.74
[57]
Prostate cancer
Mantzoros (1997) 52 51 Increment of 60 ng mL corresponded to 
an OR of 1.91 (95% CI: 1.00–3.73; 
P = 0.05)
[62]
Colorectal cancer
Nomura (2003) 282 177 (colon cancer) 
105 (rectal cancer)
Weakly positive association of IGF- I with 
colon cancer. Colon cancer cases in third 
(IGF- 1 of 137–174 ng/mL) and fourth 
quartile (IGF- 1 > 174 ng/mL) had 
increased risk compared with controls 
(OR of 2.2 and 1.8, respectively)
No association of IGFI with rectal cancer
[68]
Palmqvist (2002) 336 110 (colon cancer) 
58 (rectal cancer
Increase in colon cancer risk with 
increasing levels of IGF- 1 (OR of 2.30 and 
2.66 for third and fourth quartile, 
respectively)
Rectal cancer risk was inversely related to 
levels of IGF- 1 (OR of 0.33 and 0.33 for 
third and fourth quartile, respectively)
[69]
Tripkovic (2007) 52 52 Increase in IGF- 1 level was followed by a 
3.15- fold increased risk for developing 
colon cancer with levels of 
IGF- 1 > 310 ng/mL, whereas twice as 
many controls exhibited levels of 
IGF- 1 < 107 ng/mL
[70]
Ma (1999) 318 193 Men in the highest quintile for IGF- I had 
an increased risk of colorectal cancer 
compared with men in the lowest 
quintile (RR = 2.51; 95% CI: 1.15–5.46; 
P = 0.02)
[71]
Kaaks (2000) 200 102 Colorectal cancer risk showed a modest 
but statistically nonsignificant positive 
association with levels of IGF- I
[72]
BCa, breast cancer; OR, odds ratio; CI, confidence intervals; HR, hazard ratios; RR, relative risk; LCa, lung cancer.
1Breast cancer cases and person- years calculated from the 2284 women with IGF- I measured.
2Breast cancer cases and person- years.
Table 1. Studies of cancer risk related to IGF- 1 level. (Continued)
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levels were at risk of higher IGF- 1R activation in mam-
mary epithelial cells, which is suggested to increase survival 
of these cells with accumulating DNA damage, thereby 
facilitating stepwise carcinogenesis [49]. These results may 
indicate the importance of IGF- 1 levels in younger women 
in early life or its possible interaction with other hormones 
such as estrodial [36] and growth hormone [39]. In con-
trast to these studies, a large prospective study pooling 
two Swedish cohorts found no association between cir-
culating IGF- 1 and risk of breast cancer, regardless of 
menopausal status [50]. It is unclear why there is such 
a discrepancy in study findings. However, differences in 
findings may be due to timing of blood sampling, the 
patient cohort or the subset of breast cancer. Prospective 
studies are advantageous over retrospective studies since 
blood samples to measure IGF- 1 levels are collected before 
the clinical diagnosis of cancer and hence reverse causa-
tion (i.e., effects of an undiagnosed cancer on levels of 
IGF- 1) is less likely to play a role [50].
Estrogen plays an important role in the etiology of 
breast cancer, and there are experimental studies reporting 
cross- talk between IGF- 1 and the estrogen receptor (ER) 
in mammary cells, possibly through synergistic effects that 
contribute to breast carcinogenesis [44, 51]. Stewart et al. 
showed that estrogen increases IGF- 1 binding and IGF- 1R 
mRNA levels in the estrogen- sensitive MCF- 7 cell line by 
7- and 6.5- fold, respectively [52]. This suggests that one 
potential mechanism by which estrogen stimulates breast 
cancer cell proliferation may involve sensitization of IGF- 1 
[52].
Thus far, epidemiological evidence overall suggests a 
positive association between IGF- 1 and breast cancer risk, 
particularly in premenopausal women. Moreover, experi-
mental evidence suggests that a link between IGF- 1 and 
estrogen may explain this positive association, but perhaps 
only in breast cancers that express the estrogen 
receptor.
Lung cancer
Studies to date have investigated the association between 
IGF- 1 and lung cancer. Several studies have shown that 
circulating IGF- 1 levels were not associated with an 
increased risk of lung cancer [53–57]. One case–control 
study found a positive association between IGF- 1 and 
risk of lung cancer (OR: 2.06; 95% CI: 1.19–3.56) [21]. 
Furthermore, this study identified that the levels of IGF- 1 
and IGF- 2 in plasma were not influenced by cigarette 
smoking [21].
IGFBP- 3 is the main IGF- 1- binding protein in blood. 
IGFBP- 3 is generally considered to act as a tumor sup-
pressor gene by reducing the ability of IGF- 1 to promote 
cell survival and proliferation [58]. Although epidemio-
logical studies overall found no association for IGF- 1, a 
reduced risk of lung cancer is reported with higher cir-
culating levels of IGFBP- 3, when comparing the highest 
quartile versus lowest quartile of IGFBP- 3 in a Chinese 
prospective study (OR: 0.50, 95% CI: 0.25–1.02) [55]. 
Moreover, several meta- analyses have also reported an 
inverse association between IGFBP- 3 and risk of lung 
cancer [58, 59].
It is possible that both IGF- 1 and IGFBP- 3 contribute 
to the development of lung cancer. Cell culture studies 
have found that lung cancer cell lines, regardless of their 
Figure 1. The effects of IGF- 1 and IGF- 1R on normal and cancerous cells.
Cancer cellNormal cell
IGF-1 IGF-1
IGF-1R IGF-1R
Binds to Binds to
Proliferation ProliferationApoptosis Apoptosis
Stimulate, Inhibit, Increased levels
Transformation
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histological subtypes, have the capacity to express IGF- 1 
and its binding protein, IGFBP- 3, both in tumors and 
blood [60, 61].
Thus, until now, there is little evidence for a link 
between IGF- 1 and lung cancer risk, but an inverse asso-
ciation between IGFBP- 3 and lung cancer risk has been 
observed. These epidemiological observations are consistent 
with experimental data, which demonstrates that IGFBP- 3 
block the mitogenic and antiapoptotic effects of IGF- 1 
on lung cancer cells [21, 55].
Prostate cancer
Associations between prostate cancer and IGF- 1 have been 
studied extensively, and consistently show a positive asso-
ciation. Since 1993, it has been investigated whether higher 
circulating IGF- 1 levels are associated with an increased 
risk of prostate cancer [62, 63]. Early studies failed to 
demonstrate an association between IGF- 1 and prostate 
cancer risk. The first significant positive association between 
IGF- 1 and prostate cancer was examined in a case–control 
study by Mantzoros et al. By comparing men with prostate 
cancer to healthy controls, the odds ratio per 60 ng/mL 
increment in circulating levels of IGF- 1 was 1.91 (95% 
CI: 1.00–3.73) [64]. Furthermore, the authors also men-
tioned that this association is further reinforced by the 
lack of association between IGF- 1 and benign prostatic 
hyperplasia.
IGF- 1 is known to stimulate the growth of prostate 
cancer cells by inducing cell proliferation and inhibiting 
apoptosis [65]. The effect of IGF- 1 on prostate cancer 
cell lines has been extensively explored. For example, in 
vivo studies have shown significantly reduced proliferation 
rates in PC- 3 prostate cancer cell lines in IGF- 1- deficient 
hosts, compared to control hosts [66]. Exogenous IGF- 1 
increased the invasive potential of the DU145 prostate 
cancer cell line, which was dependent on IGF- 1R, the 
ERK MAPK pathway, and the PI3K pathway [67]. 
Furthermore, prostate cancer epithelial cells can stimulate 
their own growth by synthesizing and responding to IGF- 1 
in an autocrine manner (Fig. 2), as opposed to paracrine 
signaling [68].
Overall, epidemiological and experimental evidence to 
date suggest a positive association between circulating 
IGF- 1 and prostate cancer risk.
Colorectal cancer
Overall, studies have provided data showing that colorectal 
cancer is positively associated with IGF- 1 levels [23, 69–72]. 
Early studies in the late 1990s, suggested that high cir-
culating IGF- 1 concentrations are associated with an 
increasing risk of colorectal cancer [23, 73]. Nomura et al. 
evaluated the association between IGF- 1 and colon and 
rectal cancer separately [69]. They showed a higher risk 
of colon cancer for those with IGF- 1 levels in the third 
(137–174 ng/mL) and fourth quartiles (IGF- 1 > 174 ng/
mL) as compared to the controls (OR of 2.2 and 1.8, 
respectively). There was no association between IGF- 1 and 
rectal cancer. However, another study found a decreased 
risk of rectal cancer with high levels of circulating IGF- 1 
[70]. The authors commented that this may be due to 
rectal cancer presenting at an earlier stage than colon 
cancer, which may have masked the association with IGF- 1 
Figure 2. The autocrine and paracrine actions of IGF- 1.
IGF-1R
Cancer cell
IGF-1
Autocrine 
action
Stromal cell
IGF-1R
IGF-1
Paracrine 
action
Cancer cell
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levels [70]. On the other hand, data from two nested 
case–control study showed no statistically significant asso-
ciation between IGF- 1 and colorectal cancer risk [74, 75].
The epidemiological data on IGF- 1 and colorectal cancer 
is supported by laboratory evidence. The IGF- 1R is 
expressed in both normal colonic mucosa and human 
colorectal cancers [70]. IGF- 1 has been speculated to cause 
proliferation of colorectal cancer cells and promote over-
expression of the IGF- 1R in several studies, with no uni-
form consensus [76–79]. Furthermore, in acromegaly, a 
condition that is associated with high IGF- 1 levels, studies 
have shown that there is increased proliferation of normal 
colonic epithelium with an increased risk of developing 
colorectal adenomas and cancers in acromegaly patients 
[80, 81].
In colorectal cancer, the circulating levels of IGF- 1 is 
particularly influenced by nutritional status. Therefore, 
further research is required to investigate the role of obe-
sity, ethnicity, and dietary habits possibly as confounders 
to IGF- 1 and colorectal cancer risk.
IGF- 1 in Second Primary Cancers
This section summarizes studies on the emerging role of 
IGF- 1 in the development of SPCs with a focus on the 
definition of SPC as well as their potential link with IGF- 1 
in the case of patients with primary breast, lung, prostate, 
and colorectal cancer.
SPCs are defined as malignant tumors diagnosed at the 
same time as the primary tumor or later, which are in 
a different organ [82] and are not a metastasis or recur-
rence of the original primary cancer [83].
Breast cancer
The risk of developing a second primary breast cancer 
in a patient diagnosed with a first breast cancer has been 
studied extensively. It has been shown that in women 
with breast cancer, the risk of developing a new primary 
breast cancer in the contralateral breast is much higher 
than for healthy women developing a first breast cancer 
[84, 85]. Only a small portion of this large risk is attrib-
utable to effects of treatment: lifestyle and genetic factors 
also need to be taken into account [84], and possibly 
the role of IGF- 1 in increasing breast cancer risk.
Breast cancer is also a common SPC in itself. For 
instance, it is the most common SPC that develops in 
young women treated for Hodgkin’s lymphoma with 
supradiaphragmatic irradiation [86]. The estimates of 
cumulative risks of developing breast cancer ranged from 
35% by 40 years of age [87] to 48% by 40 years of age 
[88] after treatment. Much of this variation may be due 
to the differences in the age of diagnosis of Hodgkin’s 
lymphoma during radiation treatment, or the duration 
and dose of treatment [88, 89]. Even in the absence of 
treatment effects, in general, younger women are at a 
greater risk of developing a second primary breast cancer 
than older women [90, 91]. For instance, a cohort study 
by Hancock et al. which reviewed women treated for 
Hodgkin’s disease between 1961 and 1990 (mean follow-
 up, 10 years) concluded that the greatest risk was seen 
in young women treated before the age of 15 years (RR: 
136, 95% CI: 34–371), with a significant decline in rela-
tive risk with advancing age (above 30 years of age, RR: 
0.7, 95% CI: 0.2–1.8) [92].
From a biological point of view, the pubertal growth 
of the mammary gland is mediated predominantly by the 
actions of IGF- 1 and GH via estrogen [93]. It is postu-
lated that this mechanism may make younger women 
more prone to developing a secondary breast cancer due 
to the increased levels of both IGF- 1 and estrogen during 
puberty, and the promoting effects of IGF- 1 [41, 94]. 
According to the evidence from in situ hybridization, in 
breast cancer, IGF- 1 is predominantly expressed in the 
stromal cells (mainly fibroblasts) and very rarely in the 
breast epithelium [28, 95]. This supports the concept of 
a paracrine role of IGF- 1 in breast cancer (Fig. 2). It is 
possible that there is also an endocrine role, given that 
circulating IGF- 1 in the bloodstream is implicated in the 
malignant transformation of breast tissue [28, 43, 96]. 
IGF- 1 functions to protect breast cancer cells from apop-
tosis and induces survival [28], suggesting that locally 
synthesized IGF- 1 influences the growth of human breast 
cancer cells. It can therefore be hypothesized that IGF- 1 
produced by the stromal cells is increased in breast cancer 
(Fig. 2). This may then promote growth of a second 
primary breast cancer by entering the blood stream and 
acting in an endocrine fashion [94, 97].
Lung cancer
The lungs are often regarded as one of the most common 
organs to develop a SPC [11, 98, 99]. Common causes 
of a secondary lung cancer include a resected primary 
lung cancer, treatment- related complications in breast 
cancer and head and neck cancers [99–101], as well as 
continued smoking [102, 103]. In a US study, Johnson 
reported a 2–14% risk of developing a second lung cancer 
per person per year, with the risk increasing from twofold 
to sevenfold after 10 years of initial lung cancer diagnosis 
[104].
Head and neck cancer patients are at an increased risk 
of developing lung cancer with a standardized incidence 
ratio (SIR) of 3.75 (95% CI: 3.01–4.62) [98]. In addition, 
according to data from the Surveillance, Epidemiology, 
and End Results (SEER) registries, approximately 5% of 
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breast cancer survivors are diagnosed with a second pri-
mary lung cancer [11]. Additionally, treatment of breast 
cancer patients with radiation postmastectomy has been 
shown to approximately double the risk of second primary 
lung cancer, especially in the ipsilateral lung [99]. The 
rates of second primary lung cancer among women diag-
nosed with breast cancer before the age of 50 years is 
rising significantly, with the increase being as early as 
1 year after breast cancer diagnosis [105]. Radiotherapy 
treatment for breast cancer seems unlikely as the sole 
cause of this rise (see methodological section) because a 
long- term latency period (5–10 years) is usually associated 
with radiotherapy treatment [105]; proteins or hormones 
such as IGF- 1 should also be considered as predisposing 
factors.
When considering the biological effects of IGF- 1 in 
second primary lung cancer, it has been shown that lung 
mesenchymal cells locally synthesize IGF- 1 which acts on 
the bronchial epithelium in a paracrine manner [56]. A 
possible mechanism explaining the role of IGF- 1 in second 
primary lung cancer is that higher IGF- 1 levels detected 
in lung cancer are probably regulated by the levels of 
tissue- derived IGF- 1, but not circulating IGF- 1 [106].
Prostate cancer
The risk of all SPCs following a diagnosis of a first pri-
mary prostate cancer has been studied with variable results. 
In 1999, a Swiss study based on data collected from the 
Cancer Registries of the Swiss Cantons of Vaud and 
Neuchâtel investigated the risk of SPCs in prostate cancer 
survivors between 1974 and 1994. They found a signifi-
cantly reduced incidence rate of all cancers in men diag-
nosed with prostate cancer, compared with the general 
population (SIR: 0.7, 95% CI: 0.6–0.8) [107]. More recently, 
in 2014, a cohort study from the Swiss Canton of Zurich 
investigated the risk of SPCs in prostate cancer survivors 
between 1980 and 2010 [19]. They found an increased 
risk of SPCs among men with prostate cancer, compared 
to the general population (SIR: 1.11, 95% CI: 1.06–1.17). 
The inconsistency between these two studies may be due 
to the diagnosis of prostate cancer at an advanced stage 
with shorter survival in the earlier years of study [19]. 
Therefore, the chance of developing a SPC was lower 
than what it is currently, when prostate cancer is gener-
ally diagnosed at a less advanced stage.
When looking at specific cancer types, Davies et al. 
reported that survivors of prostate cancer had a 40% lower 
risk of developing a SPC compared to the general male 
US population; the risk was lower for leukemias and 
cancers of the oral cavity, stomach, colon, liver, lung, 
and pancreas [108]. However, they observed a higher risk 
of developing bladder [109, 110], renal, and endocrine 
cancers [111, 112]; this seems to be influenced by pelvic 
radiation therapy for prostate cancer [108]. Moreover, 
diagnostic bias is thought to play a role due to anatomy. 
However, Chrouser et al. did not observe an increased 
risk of bladder cancer after radiotherapy for prostate cancer 
[113], and there are some uncertainties in relation to the 
possible mechanism for the lack of association observed 
in this study. It is possible that there may have been an 
increased risk in this study that was not detected due to 
a short mean follow- up period of 7.1 years or likelihood 
of underreporting SPCs. Based on the current evidence, 
it seems that the risk of developing a SPC after prostate 
cancer is higher, particularly for other urological 
cancers.
Prostate cancer is also commonly observed as a SPC 
in itself. Kok et al. concluded that in the first year fol-
lowing a first cancer diagnosis, male cancer survivors have 
a 30% increased risk of developing prostate cancer as a 
SPC, partly due to increased diagnostic activity of the 
urological organs or incidental finding following health 
check- ups [114]. Other studies have also shown an excess 
risk of developing prostate cancer as a SPC after a diag-
nosis of a bladder cancer as a first cancer [115, 116]. In 
addition, cancer survivors diagnosed with a first primary 
urological cancer may request for prostate- specific antigen 
(PSA) testing as a consequence of anxiety or persisting 
urological symptoms [114]. Furthermore, survivors of 
melanoma are also at increased risk of developing prostate 
cancer [117].
In contrast to the biological mechanisms of breast and 
lung cancer, prostate cancer epithelial cells can stimulate 
their own growth by synthesizing and responding to IGF- 1 
[65, 68]. Furthermore, there is evidence that IGF- 1 enhances 
the adhesion of prostate cancer cells and this promotes 
prostate cancer metastasis, possibly through the actions 
of IL- 17 [118]. The potential data does not suggest a 
direct causative role for IGF- 1 signaling in the progression 
and invasiveness of prostate cancer. The IGF- 1 pathway 
activates a number of downstream signaling pathways, 
including the phosphatidylinositol- 3 kinase (PI3- K) path-
way, the protein kinase C pathway, the CREB pathway, 
and the mitogen- activated protein kinase (MAPK) pathway. 
These pathways contribute to prostate cancer through 
deregulation and constitutive activation of the pathway 
[67]. While the etiology of IGF- 1 in second primary pros-
tate cancer is unknown, it is plausible that those who 
develop prostate cancer may possess a common genetic, 
hormonal, or environmental factor that protects them 
from developing a SPC [119]. Prostate cancer survivors 
have a lower risk of developing cancers of the stomach, 
lung, and pancreas [108, 120], raising the question of 
whether these patients are “protected” against these malig-
nancies, or whether it is simply that they are above the 
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age at which the risk of these tumors typical peak, which 
is at an earlier age [119].
Colorectal cancer
Several studies have demonstrated an increased risk of 
developing secondary colorectal cancer following radio-
therapy exposure, in particular, rectal cancer following 
radiation for prostate cancer and colorectal cancer fol-
lowing abdominopelvic radiation for cervical cancer. 
Brenner et al. investigated the risk in prostate cancer 
patients who underwent radiotherapy or surgery and 
reported a significantly increased risk of rectal cancer in 
the radiotherapy group, particularly for long- term survi-
vors, when comparing with the surgery group [121]. 
Furthermore, Baxter et al. observed a significant increase 
in the development of rectal cancer postradiation for 
prostate cancer [122]. However, radiation did not promote 
development of cancer in the remainder of the colon, 
suggesting that the effect of radiation is limited directly 
to irradiated tissue. In addition to prostate cancer patients, 
cervical cancer patients also seem to be at risk of devel-
oping colon cancer, as observed by Chatruvedi et al. [123].
In normal colonic tissue, IGF- 1 binds with high affinity 
to the IGF- 1R and activates specific insulin receptor sub-
strates, which can modulate several downstream pathways 
involved in gene transcription, cell proliferation, and 
apoptosis [124]. Although the etiology of IGF- 1 in second 
primary colorectal cancer is unknown, based on findings 
from normal colonic tissues, we can speculate about the 
potential complexity of this carcinogenic mechanism. With 
the exposure to radiotherapy, one hypothesis suggests that 
in individuals with higher IGF bioactivity, there is enhanced 
survival of partially transformed cells which leads to a 
larger pool of targets for subsequent “hits” initiating colo-
rectal carcinogenesis via the process of stepwise carcino-
genesis and malignant transformation. A second hypothesis 
suggests that the time needed for the progression of a 
fully transformed cell to fully developed cancer is inversely 
associated with IGF bioactivity [69].
Methodological considerations for 
epidemiological studies investigating the 
link between IGF- 1 and risk of second 
primary cancers
In the clinical setting, it may be problematic to absolutely 
define whether the second tumor is in fact a SPC or a 
recurrence or a metastasis, and a definitive diagnosis may 
only be possible histologically. Whether the results showed 
in this review were strictly according to the standard are 
unclear, so therefore we need to consider the results with 
caution.
Even though several studies suggest a link between IGF- 1 
and development of SPCs, several methodological issues 
need to be considered when assessing these epidemiologi-
cal findings. Firstly, diagnostic bias may occur when the 
SPC is the main outcome of interest, as it may be detected 
following a diagnostic intervention related to the first 
primary tumor [115]. Aside from diagnostic activity, treat-
ment related to this first primary tumor may also increase 
the risk of developing a second primary tumor (e.g., 
chemotherapy and radiation therapy) [115, 125].
Secondly, when evaluating the effect of IGF- 1 on SPCs, 
one has to consider sources of errors that cause misclas-
sification of this biomarker. Nondifferential misclassifica-
tion of IGF- 1 may occur due to laboratory errors (e.g., 
specimen collection, processing, and storage) or changes 
in IGF- 1 assays [126]. In addition, a single measurement 
of IGF- 1 may not reflect the actual underlying levels. 
Repeated measurements would reflect long- term exposure 
and may be useful in the context of carcinogenesis [127]. 
Aside from misclassification of data for IGF- 1, it is also 
possible to have misclassification related to the SPCs 
because it is not always possible from a pathological point 
of view to make a distinction between local recurrences, 
metastases, or a true SPC.
Thirdly, when studying the association between IGF- 1 
and SPCs, one has to be aware of potential confounders 
such as smoking or treatment. In the case of lung cancer, 
the effect of current and past smoking needs to be removed 
to maximize the efficiency of the study [56] as some 
studies have shown that smoking decreases the levels of 
IGF- 1 [128], while others have found no relationship 
[129]. It is therefore possible that cigarette- related car-
cinogen exposure may overshadow the more subtle effects 
of IGF- 1 on cancer development, which could explain 
the general lack of an association between IGF- 1 and risk 
of lung cancer [54]. As a result, smoking may have an 
effect on IGF- 1 levels as well as the risk of developing 
a SPC, but it is unlikely to be an intermediate in the 
pathway between IGF- 1 and SPCs [130]. Furthermore, 
treatment received for the primary cancer may confound 
the association between IGF- 1 and SPCs [114, 130]. 
Similarly to smoking, treatment may also alter the effect 
of IGF- 1 as well as the risk of developing a SPC, but it 
is again unlikely to be an intermediate in the pathway 
between IGF- 1 and SPCs [130].
Conclusion
In spite of a consistent positive observation between IGF- 1 
and risk of first primary cancers (especially breast, prostate, 
and colorectal), the evidence for the role of IGF- 1 in the 
development of SPCs is less clear. Some of the evidence 
we gathered came from targeting the IGF system in cell 
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culture studies, and therefore, we need to see the results 
with caution on whether it can be compared to clinical 
situations. However, the relevant influences of these path-
ways in SPCs are unknown. This lack of an association 
may be partly explained by methodological issues. With 
respect to the biological pathway, there is consistent evi-
dence for the mitogenic role of IGF- 1 in carcinogenesis 
by increasing cell proliferation and inhibiting apoptosis. 
However, experimental studies highlight uncertainties 
regarding the role of IGF- 1 in the development of SPCs. 
More observational studies are needed to further under-
stand the role of IGF- 1 in the development of specific 
SPCs, as well as to determine which pathways downstream 
of the IGF- 1R are involved in this process.
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